Last reviewed · How we verify
TDENV-LAV F17
At a glance
| Generic name | TDENV-LAV F17 |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine (PHASE1)
- TDENV PIV and LAV Dengue Prime-boost Strategy (PHASE1)
- TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDENV-LAV F17 CI brief — competitive landscape report
- TDENV-LAV F17 updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI